Signet Health

signethealth.com

Signet Health assists its hospital clients with the development and management of acute behavioral health and inpatient rehabilitation solutions. Signet's senior level leadership has a combined average of 31 years experience in mental health and acute rehab management in client hospitals across the nation. Our Operations team brings the highest level of operational expertise and experience in the fields of mental health and physical medicine/rehab to our client hospitals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industry Outlook

SLINGSHOT BIOSCIENCES UNVEILS REVOLUTIONARY FLUORESCENT PROTEIN CONTROL SERIES TO ENHANCE FLOW CYTOMETRY ANALYSIS

Businesswire | July 17, 2023

news image

Slingshot Biosciences, Inc. a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraComp fluorescent protein series collection. This groundbreaking series provides scientists with a cutting-edge fluorescent protein control platform for use in flow cytometry analysis. By genetically modifying T cells and other immune cells in humanized mice to express fluorescent reporter proteins, including eGFP and mCherry, scientists are able to obs...

Read More

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

news image

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More

NUCLEUS BIOLOGICS UNVEILS WORLD'S FIRST ONLINE PORTAL FOR INSTANTANEOUS CUSTOM CGMP CELL CULTURE MEDIA CONFIGURATION

Nucleus Biologics | May 27, 2020

news image

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™, an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000 liters.Media is a critical component in the production of cell therapies. During development, companies iteratively test multiple formulation...

Read More

Research

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

news image

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More
news image

Cell and Gene Therapy, Industry Outlook

SLINGSHOT BIOSCIENCES UNVEILS REVOLUTIONARY FLUORESCENT PROTEIN CONTROL SERIES TO ENHANCE FLOW CYTOMETRY ANALYSIS

Businesswire | July 17, 2023

Slingshot Biosciences, Inc. a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraComp fluorescent protein series collection. This groundbreaking series provides scientists with a cutting-edge fluorescent protein control platform for use in flow cytometry analysis. By genetically modifying T cells and other immune cells in humanized mice to express fluorescent reporter proteins, including eGFP and mCherry, scientists are able to obs...

Read More
news image

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More
news image

NUCLEUS BIOLOGICS UNVEILS WORLD'S FIRST ONLINE PORTAL FOR INSTANTANEOUS CUSTOM CGMP CELL CULTURE MEDIA CONFIGURATION

Nucleus Biologics | May 27, 2020

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™, an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000 liters.Media is a critical component in the production of cell therapies. During development, companies iteratively test multiple formulation...

Read More
news image

Research

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More